The discovery of novel and potent indazole NLRP3 inhibitors enabled by DNA-encoded library screening

  • Bioorg Med Chem Lett. 2024 Feb 28:102:129675. doi: 10.1016/j.bmcl.2024.129675.
George Hartman  1 Paul Humphries  2 Robert Hughes  2 Andrew Ho  2 Rusty Montgomery  2 Aditi Deshpande  2 Maitriyee Mahanta  2 Sarah Tronnes  2 Samantha Cowdin  2 Xu He  3 Fangchao Liu  3 Lifang Zhang  3 Chuan Liu  3 Dengfeng Dou  3 Jin Li  3 Aleksander Spasic  4 Rebecca Coll  5 Michael Marleaux  6 Inga V Hochheiser  6 Matthias Geyer  6 Paul Rubin  2 Kristen Fortney  2 Kevin Wilhelmsen  2
Affiliations
  • 1. BioAge Labs, 1445 S. 50(th) St. Richmond, CA 94804, USA. Electronic address: [email protected].
  • 2. BioAge Labs, 1445 S. 50(th) St. Richmond, CA 94804, USA.
  • 3. HitGen Inc., Shuangliu District, Chengdu, Sichuan 610000, China.
  • 4. WuXi AppTec, 22 Strathmore Road, Natick, MA 01760, USA.
  • 5. Wellcome-Wolfson Institute for Experimental Medicine, Queen's University Belfast, Belfast BT9 7BL, UK.
  • 6. Institute of Structural Biology, University of Bonn, Venusberg-Campus 1, 53127, Bonn, Germany.
Abstract

NLRP3 is an intracellular sensor protein that detects a broad range of danger signals and environmental insults. Its activation results in a protective pro-inflammatory response designed to impair pathogens and repair tissue damage via the formation of the NLRP3 inflammasome. Assembly of the NLRP3 inflammasome leads to Caspase 1-dependent secretory release of the pro-inflammatory cytokines IL-1β and IL-18 as well as to gasdermin d-mediated pyroptotic cell death. Herein, we describe the discovery of a novel indazole series of high affinity, reversible inhibitors of NLRP3 activation through screening of DNA-encoded libraries and the potent lead compound 3 (BAL-0028, IC50 = 25 nM) that was identified directly from the screen. SPR studies showed that compound 3 binds tightly (KD range 104-123 nM) to the NACHT domain of NLRP3. A CADD analysis of the interaction of compound 3 with the NLRP3 NACHT domain proposes a binding site that is distinct from those of ADP and MCC950 and includes specific site interactions. We anticipate that compound 3 (BAL-0028) and Other members of this novel indazole class of neutral inhibitors will demonstrate significantly different physical, biochemical, and biological properties compared to NLRP3 inhibitors previously identified.

Keywords
Anti-inflammation; BAL-0028; CADD; DNA-encoded library; IL-18; IL-1β; NLRP3 inflammasome; NLRP3 inhibitor; Pyroptosis; STAND ATPase.
Products